share_log

PRISMBio---反発、E7386とレンバチニブメシル酸塩との併用試験の結果が「欧州臨床腫瘍学会年次総会」で発表へ

PRISM Bio - The results of the combination trial with E7386 and lenvatinib mesylate will be presented at the European Clinical Oncology Society Annual Meeting.

Fisco Japan ·  Sep 9 00:11


Opposition: Today, it was announced that the results of the combination test of E7386 and lenvatinib mesylate, which were co-created by the company and Eisai, will be presented at the “European Society of Clinical Oncology Annual Meeting (ESMO Congress 2024)” by Eisai, and it is viewed as good material. Manageable safety of combined use of E7386 and lenvatinib has been shown, and preliminary antitumor effects have also been confirmed, and administration to the remaining patients is continuing.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment